Publications

2017

Badal-Faesen S, Firnhaber C, Kendall MA, Wu X, Grinsztejn B, de Silva Escada RO, Fernandez M, Hogg E, Sanne I, Johnson P, Alland D, Mazurek GH, Benator DA, Luetkemeyer AF, the ACTG A5295 and Tuberculosis Trials Consortium Study 34 Teams. Impact of larger Sputum Voume on Xpert MTB/RIF Assay Detection of Mycobacterium tuberculosis in Smear-Negative Individuals with Suspected Tuberculosis. Journal of Clinical Medicine 2017, 6(78):1-4.
https://www.ncbi.nlm.nih.gov/pubmed/26839383

 

Brennan AT, Bor J, Davies MA, Conradie F, Maskew M, Long L, Sanne I and Fox M. Tenofovir stock shortages have limited impact on clinic-and-patient-level HIV treatment outcomes in public sector clinics in South Africa. Tropical Medicine and International Health, February 2017; 22(2):241-251
https://www.ncbi.nlm.nih.gov/pubmed/27862762

 

Brennan AT, Davies MA, Bor J, Wandeler G, Stinson K, Wood R, Prozesky H, Tanser F, Fatti G, Boulle A, Sikazwe I, Wool-Kaloustian K, Yuannoutsos C, Leroy V, de Rekeneire N and Fox MP. Has the phasing out of stavudine in accordance with changes in WHO guidelines led to a decrease in single-drug substitutions in first-line antiretroviral therapy in HIV in sub-Saharan Africa? AIDS 201, 31(1), 147-157
https://www.ncbi.nlm.nih.gov/pubmed/27776039

 

Celum C, Hong T, Cent A, Donnell D, Morrow R, Baeten JM, Firnhaber C, Grinsztejn B, Hosseinipour MC, Lalloo U, Nyirenda M, Riviere C, Sanchez J, Santos B, Supparatpinyo K, Hakim J, Kumarasamy N, Campbell TB and the ACTG PEARLS/A5175 Team. Herpes Simplex Virus Type 2 Acquisition Among HIV-1-Infected Adults Treated with Tenofovir Disoproxyl Fumarate as Part of Combination Antiretroviral Therapy: Results from the ACTG A5175 PEARLS Study. The Journal of Infectious Diseases, 2017.
https://www.ncbi.nlm.nih.gov/pubmed/28453835

 

Chiu C, Johnson L, Jamieson L, Larson BA and Meyer Rath. Designing an optimal HIV programme for South Africa: Does the optimal package change when diminishing returns are considered? BMC Public Health 2017, 17:143.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5282636/

 

Clouse K, Vermund SH, Maskew M, Lurie MN, MacLeod W, Malete G, Carmona S, Sherman G and Fox MP. Mobility and Clinic Swtiching Among Postpartum Women Considered Lost to HIV Care in South Africa. Journal of Acquired Immune Deficiency Syndrome (JAIDS), 74:4, 383-389.
https://www.ncbi.nlm.nih.gov/pubmed/28225717

 

De Waal R, Cohen K, Fox MP, Stinson K, Maartens G, Boulle A, Igumbor EU and Davies MA. Changes in estimated glomerular filtration rate over time in South African HIV-1-infected patients receiving tenofovir: a retrospective cohort study. Journal of International AIDS Society (JIAS), 2017, 20:21317, pp-tbc.
https://www.ncbi.nlm.nih.gov/pubmed/28406595

 

Firnhaber C et al. Prevalence of Anal HPV and Anal Dysplasia in HIV-Infected Women from Johannesburg, South Africa. JAIDS 2017.
https://www.ncbi.nlm.nih.gov/pubmed/28141783

 

Fox MP, Maskew M, Brennan AT, Evans D, Onoya D, Malete G, MacPhail P, Basset J, Ebrahim O, Mabotja D, Mashamaite S, Long L, and Sanne I. Cohort profile: Right to Care Clinical HIV Cohort, South Africa.
https://www.ncbi.nlm.nih.gov/pubmed/28601835

 

Fox MP and Rosen S. A new cascade of HIV care for the era of “treat all”. PLOS Medicine Open Access, April 11, 2017, 1-8.
http://journals.plos.org/plosmedicine/article/file?id=10.1371/journal.pmed.1002268&type=printable

 

Jamieson L, Evans D, Brennan AT, Moyo F, Spencer D, Mahomed K, Maskew M, Long L, Rosen S and Fox MP. Changes in elevated cholesterol in the era of tenofovir in South Africa: risk factors, clinical management and outcomes. HIV Medicine 2017.
https://www.ncbi.nlm.nih.gov/pubmed/28332270

 

Maskew M, Bor J, Hendrickson C, MacLeod W, Barnighausen T, Pillay D, Sanne I, Carmona S, Stevens W and Fox MP. Imputing HIV treatment start dates from routine laboratory data in South Africa: a validation study. BMC Health Services (2017) 17:41, 1-9.
https://www.ncbi.nlm.nih.gov/pubmed/28095905

 

Mikkelsen E, Hontelez JAC, Jansen MPM, Barnighausen, Hauck K, Johansson KA, Meyer-Rath G, Over M, de Vlas SJ, van der Wilt GJ, Bijlmakers L and Baltussen RMPM. Evidence for scaling up HIV treatment in sub-Saharan Africa: A call for incorporating health system constraints. PLOS Medicine, February 2017, 1-5.
http://repository.ubn.ru.nl/browse?type=author&authority=173428525

 

Achhra AC, Mocroft A, Ross M, Ryom-Nielson L, Avihingsanon A, Bakowska E, Belloso W, Clarke A, Furrer H, Lucas GM, Ristola M, Rassool M, Ross J, Somboonwit C, Sharma S, Wyatt C. Impact of early versus deferred antiretroviral therapy on estimated glomerular filtration rate in HIV-positive individuals in the START trial. Int J Antimicrob Agents. 2017 Sep;50(3):453-460.doi:10.1016/j.ijantimicag. 2017.04.021. Epub 2017 Jun 28. PMID: 28668686. ISSN: 0924-8579. 10.1016/j.ijantimicag.2017.04.021
https://www.ncbi.nlm.nih.gov/pubmed/28668686

 

Badal-Faesen S, Firnhaber C, Kendall MA, Wu X, Grinsztejn B, de Silva Escada RO, Fernandez M, Hogg E, Sanne I, Johnson P, Alland D, Mazurek GH, Benator DA, Luetkemeyer AF, the ACTG A5295 and Tuberculosis Trials Consortium Study 34 Teams. Impact of larger Sputum Voume on Xpert MTB/RIF Assay Detection of Mycobacterium tuberculosis in Smear-Negative Individuals with Suspected Tuberculosis. Journal of Clinical Medicine 2017, 6(78):1-4. Doi:10.3390/jcm6080078
https://www.ncbi.nlm.nih.gov/pubmed/26839383

 

Belaunzarán-Zamudio PF, Azzoni L, Canaday DH, Caro-Vega YN, Clagget B, Rassool MS, Rodriguez B, Sanne I, Sereti I, Sierra-Madero JG, Lederman MM. Immunologic Effects of Maraviroc in HIV-Infected Patients with Severe CD4 Lymphopenia Starting Antiretroviral Therapy: A Sub-Study of the CADIRIS Trial. Pathog Immun. 2017;2(2):151-177. doi: 10.20411/pai.v2i2.181. Epub 2017 May 9. PMID: 28736763. ISSN: 2469-296
https://www.ncbi.nlm.nih.gov/pubmed/28736763

 

BerryKM,Parker W,MchizaZJ,SewpaulR,Labadarios D,RosenS,StokesA.Quantifyingunmetneed forhypertension careInSouthAfricathroughacarecascade:evidencefromtheSANHANES,2011-2012. BMJGlobal Health, August 2017, 2: e000348, pp 1-10. Doi: 10.1136/bmjgh-2017-000348
https://www.ncbi.nlm.nih.gov/pubmed/29082013

 

Bisson GP, Ramchandani R, Miyahara S, Mngqibisa R, Matoga M, Ngongondo M, Samaneka W, Koech L, Naidoo K, Rassool M, Kirui F, Banda P, Mave V, Kadam D, Leger P, Henostroza G, Manabe YC, Bao J, Kumwenda J, Gupta A, Hosseinipour MC; Adult AIDS Clinical Trials Group A5274 (REMEMBER) Study Team. Risk factors for early mortality on antiretroviral therapy in advanced HIV-infected adults. AIDS. 2017 Jul 24. doi: 10.1097/QAD.0000000000001606.
PMID: 28742529
https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&db=pubmed&term=Miyahara%20S%5Bau%5D&dispmax=50

 

Boeree MJ, Heinrich N, Aarnoutse R, Diacon AH, Dawson R, Rehal S, Kibiki GS, Churchyard G, Sanne I, Ntinginya NE, Minja LT, Hunt RD, Charalmbous S, Hanekom M, Semvua HH, Mpagama SG, Manyama C, Mtafaya B, Reither K, Wallis RS, Venter A, Narunsky K, Mekota A, Henne S, Colbers A, van Balen GP, Gillespie SH, Phillips PP, Hoelscher M; PanACEA consortium. High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial. January 2017, Lancet Infectious Disease, 17:1, pp 39-49. 10.1016/s1473-3099(16)30274-2
https://researchonline.lshtm.ac.uk/3415031/1/High-dose%20rifampicin%2C%20moxifloxacin%2C%20and%20SQ109.pdf

 

BorJ,Ahmed S, FoxMP, RosenS, Meyer-RathG, KatzIT, TanerF, Pillay D .Effectofeliminating CD4-countthresholds on HIVtreatmentinitiationinSouth Africa: An empirical modellingstud. PLoSONE, June 2017, 12:6. Doi: 10.137/journal.pone.0178249
https://www.ncbi.nlm.nih.gov/pubmed/28617805

 

Brennan AT, Bor J, Davies MA, Conradie F, Maskew M, Long L, Sanne I and Fox M. Tenofovir stock shortages have limited impact on clinic-and-patient-level HIV treatment outcomes in public sector clinics in South Africa. Tropical Medicine and International Health, February 2017; 22(2):241-251. 10.111/tmi.12811
https://www.ncbi.nlm.nih.gov/pubmed/27862762

 

Brennan AT, Davies MA, Bor J, Wandeler G, Stinson K, Wood R, Prozesky H, Tanser F, Fatti G, Boulle A, Sikazwe I, Wool-Kaloustian K, Yuannoutsos C, Leroy V, de Rekeneire N and Fox MP. Has the phasing out of stavudine in accordance with changes in WHO guidelines led to a decrease in single-drug substitutions in first-line antiretroviral therapy in HIV in sub-Saharan
Africa? AIDS 2017, 31(1), 147-157.
https://www.ncbi.nlm.nih.gov/pubmed/27776039

 

Cahn P, Kaplan R, Sax PE, Squires K, Molina JM, Avihingsanon A, Ratanasuwan W, Rojas E, Rassool M, Bloch M, Vandekerckhove L, Ruane P, Yazdanpanah Y, Katlama C, Xu X, Rodgers A, East L, Wenning L, Rawlins S, Homony B, Sklar P, Nguyen BY, Leavitt R, Teppler H; ONCEMRK Study Group. Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial.Lancet HIV. 2017 Nov;4(11):e486-e494. doi: 10.1016/S2352-3018(17)30128-5. Epub 2017 Sep 11.
https://www.ncbi.nlm.nih.gov/pubmed/28918877

 

Celum C, Hong T, Cent A, Donnell D, Morrow R, Baeten JM, Firnhaber C, Grinsztejn B, Hosseinipour MC, Lalloo U, Nyirenda M, Riviere C, Sanchez J, Santos B, Supparatpinyo K, Hakim J, Kumarasamy N, Campbell TB and the ACTG PEARLS/A5175 Team. Herpes Simplex Virus Type 2 Acquisition Among HIV-1-Infected Adults Treated With Tenofovir Disoproxyl Fumarate as Part of Combination Antiretroviral Therapy: Results from the ACTG A5175 PEARLS Study. The Journal of Infectious Diseases, 2017.
https://www.ncbi.nlm.nih.gov/pubmed/28453835

 

Chiu C, Johnson L, Jamieson L, Larson BA and Meyer RathG. Designing an optimal HIV programme for South Africa: Does the optimal package change when diminishing returns are considered? BMC Public Health, January 2017, 17:143. 10.1186/212889-017-4023-3
https://bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-017-4023-3

 

Clouse K, Mongwenyana C, Musinda M, Bokaba D, Long L, Maskew M, Ahonkhai A, Fox MP. Acceptability and feasibility of a financial incentive intervention to improve retention in HIV care among pregnant women in Johannesburg, South Africa. AIDS Care, October 2017,
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4370783/

 

Clouse K, Vermund SH, Maskew M, Lurie MN, MacLeod W, Malete G, Carmona S, Sherman G and Fox MP. Mobility and Clinic Switching Among Postpartum Women Considered Lost to HIV Care in South Africa. Journal of Acquired Immune Deficiency Syndrome (JAIDS), April 2017, 74:4, 383-389.
https://www.ncbi.nlm.nih.gov/pubmed/28225717

 

Cornell M, Johnson LF, Wood R, Tanser F, Fox MP, Prozesky H, Schomaker M, Effer M, Davies MA, Boulle A for the IEDEA Southern Africa collaboration. JIAS, September 2017, 20:21902.
http://scholar.sun.ac.za/bitstream/handle/10019.1/104591/cornell_mortality_2018.pdf?sequence=1&isAllowed=y

 

De Waal R, Cohen K, Fox MP, Stinson K, Maartens G, Boulle A, Igumbor EU and Davies MA. Changes in estimated glomerular filtration rate over time in South African HIV-1-infected patients receiving tenofovir: a retrospective cohort study. Journal of International AIDS Society (JIAS), 2017, 20:21317, pp 1-8. 10.7448/ias.20.1.21317
https://www.ncbi.nlm.nih.gov/pubmed/28406595

 

ErlandsonKM,FiorilloSP,CardosoSW,RiviereC,Sanchez J, HakimJ,KumarasamyN,Badal-FaesenS,LallooU,KumwendaJ, CampbellTB,BrownTT.Insulin-LikeGrowthFactorIsAssociated withChangesinBodyCompositionwithAntiretroviralTherapy Initiation.AIDSResHumRetroviruses.2017Sep;33(9):929-934. doi:10.1089/AID.2016.0327.Epub2017May16.PubMedPMID: 28403619;PubMedCentralPMCID:PMC5576217.
https://www.ncbi.nlm.nih.gov/pubmed/28403619

 

EshlemanSH,WilsonEA,ZhangXC,OuSS,Piwowar-ManningE, EronJJ,McCauleyM,GambleT,GallantJE,HosseinipourMC, KumarasamyN,HakimJG,KalongaB,PilottoJH,GrinsztejnB, GodboleSV,ChotirosniramitN,SantosBR,ShavaE,MillsLA, PanchiaR,MwelaseN,MayerKH,ChenYQ,Cohen MS,Fogel JM. Virologicoutcomesinearlyantiretroviraltreatment:HPTN052.HIVClinTrials. 2017May;18(3):100-109.doi:10.1080/ 15284336.2017.1311056.Epub2017Apr7.PubMed PMID:28385131.
https://www.ncbi.nlm.nih.gov/pubmed?linkname=pubmed_pubmed&from_uid=28385131

 

Evans D, Schnippel K, Govathson C, Sineke T, Black A, Long L, Berhanu R, Rosen S. Treatment initiation among persons diagnosed with drug resistant tuberculosis in Johannesburg, South Africa. Open Access, PLOS One, July 2017.
https://www.researchgate.net/publication/318714358_Treatment_initiation_among_persons_diagnosed_with_drug_resistant_tuberculosis_in_Johannesburg_South_Africa

 

FennerL, AtkinsonA, BoulleA, FoxM, ProzeskyH, ,ZurcherK, BallifM, Furrer H, Zwahlen, M, DaviesM, EggerM.HIV viral loadasanindependentriskfactorfortuberculosisinSouthAfrica: collaborativeanalysisofcohortstudies. JIASJune 2017, 20:21327. 10.7448/IAS.20.1.21327
https://www.ncbi.nlm.nih.gov/pubmed/28691438

 

Ferrian S, Manca C, Lubbe S, Conradie F, Ismail N, Kaplan G, Gram CM, Fallows D. A combination of baseline plasma immune markers can predict therapeutic response in multidrug resistant tuberculosis. PLOS One, May 2017. 10.1371/journal.pone.0176660
https://www.ncbi.nlm.nih.gov/pubmed/28464011

 

Firnhaber C, Swarts A, Goeieman B, Rakhombe N, Mulongo M, Williamson AL, Michelow P, Ramotshela S, Faesen M, Levin S, Wilkins T. Cryotherapy reduces progression of cervical intraepithelial neoplasia grade 1 in South African HIV-infected women: a randomized, controlled trial.J Acquir Immune Defic Syndr. 2017 Sep 7. doi: 10.1097/QAI.0000000000001539. PMID: 28902073
https://www.ncbi.nlm.nih.gov/pubmed/28902073

 

Fox MP, Maskew M, Brennan AT, Evans D, Onoya D, Malete G, MacPhail P, Basset J, Ebrahim O, Mabotja D, Mashamaite S, Long L, and Sanne I. Cohort profile: Right to Care Clinical HIV Cohort, South Africa. Open Access, BMJ 2017. doi:10.1136/bmjopen-2016-015620,
https://www.ncbi.nlm.nih.gov/pubmed/28601835

 

Fox MP and Rosen S. A new cascade of HIV care for the era of “treat all”. PLOS Medicine Open Access, April 11, 2017, 1-8. 10.1371/journal.pmed.1002268
https://www.ncbi.nlm.nih.gov/pubmed/21811403

 

GoeiemanBJ,FirnhaberCS,JongE,MichelowP,KegorilweP, SwartsA,WilliamsonAL,AllanB,SmithJS,WilkinTJ.Prevalence of Anal HPV and AnalDysplasiainHIV-InfectedWomenfromJohannesburg,SouthAfrica.JAcquirImmuneDefic Syndr. 2017Jul
1;75(3):e59-e64. doi:10.1097/ QAI.0000000000001300.PubMed PMID: 28141783;PubMedCentralPMCID:PMC5472492
https://www.ncbi.nlm.nih.gov/pubmed/28141783

 

GreerAE,OuSS,WilsonE,Piwowar-ManningE,FormanMS, McCauleyM,GambleT, RuangyuttikarnC,HosseinipourMC, KumarasamyN,NyirendaM,GrinsztejnB,PilottoJH, KosashunhananN,GonçalvesdeMeloM,MakhemaJ,AkeloV, PanchiaR,Badal-FaesenS,ChenYQ,Cohen MS,EshlemanSH, ThioCL,ValsamakisA.A Comparisonof HepatitisBVirusInfectioninHIV-infectedandHIV-uninfectedParticipantsEnrolledinaMulti-NationalClinicalTrial:HPTN052.JAcquirImmuneDeficSyndr. 2017Jul26.doi:10.1097/QAI.0000000000001511. PubMedPMID: 28749822.
https://www.ncbi.nlm.nih.gov/pubmed/28749822

 

Hoffman R, Bardon A, Rosen S, Fox M, Kalua T, Xulu T, Taylor A and Sanne I. Varying Intervals of antiretroviral medication dispensing to improve outcomes for HIV patients (The INTERVAL Study): study protocol for a randomized controlled trial. BioMed Central, Open Access, 18: 476. Doi 10.1186/s13063-017-2177-z.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5640907/

 

Hoy JF, Grund B, Roediger M, Schwartz AV, Shepherd J, Avihingsanon A, Badal-Faesen S de Wit S, Jacoby S, La Rosa A, Pujari S, Schechter M, White D, Engen NW, Ensrud K, Aagaard PD, Carr A,; INSIGHT START Bone Mineral Density Substudy Group. Immediate Initiation of Antiretroviral Therapy for HIV Infection Accelerates Bone Loss Relative to Deferring Therapy: Findings from the START Bone Mineral Density Substudy, a Randomized Trial.Journal of Bone Mineral Research, June 2017. Doie: 10.1002/jbmr.3183. PMID: 28650589
https://www.ncbi.nlm.nih.gov/pubmed/28650589

 

Jamieson L, Evans D, Brennan AT, Moyo F, Spencer D, Mahomed K, Maskew M, Long L, Rosen S and Fox MP. Changes in elevated cholesterol in the era of tenofovir in South Africa: risk factors, clinical management and outcomes. HIV Medicine 2017. September 2017, 18:8, pp 595–603. Doi: 10. 1111/hiv.12495.
https://www.ncbi.nlm.nih.gov/pubmed/28650589

 

Lince-Deroche N, van Rensburg C, Masuku S, Rayne S, Benn C, Holele P. Breast cancer in South Africa: developing an affordable and achievable plan to improve detection and survival. Chapter 17, 2017 South African Health Report.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5646900/

 

Lippman SA, Pettifor A, Rebombo D, Julien A, Wagner RG, Kang Dufour MS, Kabudula CW, Neilands B, Twine R, Gottert A Gomez-olive FX, Tollman SM, Sanne I, Peacock D, Khan K. Evaluation of the Tsima community mobilization intervention to improve engagement in HIV testing and care in South Africa: study protocol for a cluster randomized trial. Implement Science, January 2017, 12:1, 9. Doi:
http://www.mrc.ac.za/sites/default/files/publications/2018-06-20/Publications2016-17.pdf

 

Long L, Maskew M, Brennan AT, Mongwenyana C, Nyoni C, Malete G, Sanne I. Fox MP, and Rosen S. Initiating antiretroviral therapy for HIV at a patient’s first clinic visit: a cost-effectiveness analysis of the rapid initiation of treatment randomized controlled trial. April 2017, 31:11, pp 1611-1619.
https://www.ncbi.nlm.nih.gov/pubmed/28463879

 

Manion M, Andrade BB, DerSimonian R, Gu W, Rupert A, Musselwhite LW, Sierra Madero JG, Belaunzaran-Zamudio PF, Sanne I, Lederman MM, Sereti I. Country of residence is associated with distinct inflammatory biomarker signatures in HIV-infected patients. Journal of Virus Eradication. January 2017, 3:1, pp 24-33.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5337418/

 

Maskew M, Bor J, Hendrickson C, MacLeod W, Barnighausen T, Pillay D, Sanne I, Carmona S, Stevens W and Fox MP. Imputing HIV treatment start dates from routine laboratory data in South Africa: a validation study. BMC Health Services, 2017, 17:41, 1-9. Doi:10.1186/s12913-016-1940-2.
https://www.ncbi.nlm.nih.gov/pubmed/28095905

 

Mbulawa ZZA, Wilkin T, Goeieman BJ, Jong E, Michelow P, Swarts A, Smith JS, Kegorilwe P, Firnhaber CS, Williamson AL. Prevalence of Anal Human Papillomavirus (HPV) and Performance of Cepheid Xpert and Hybrid Capture 2 (hc2) HPV Assays in South African HIV-Infected Women.Am J Clin Pathol. 2017 Aug 1;148(2):148-153. doi: 10.1093/ajcp/aqx050. PMID:28898982
https://www.ncbi.nlm.nih.gov/pubmed/28898982

 

Meyer-Rath G, Johnson LF, Pillay Y, Blecher M, Brennan AT, Long L, Moultrie H, Sanne I, Fox MP and Rosen S. Changing the South African National Antiretroviral therapy guidelines: The role of cost modelling. Open Access, PLOS One, October 2017. 10.1371/journal.pone.0186557.
https://www.ncbi.nlm.nih.gov/pubmed/29084275

 

Meyer-Rath G, van Rensburg C, Larson B, Jamieson L, Rosen S. Revealed willingness-to-pay versus standard cost-effectiveness thresholds: Evidence from the South African HIV Investment Case. Open Access, PLOS One, October 2017. Doi.org/ 10.1371/journal.pone.0186496
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5658054/

 

Mikkelsen E, Hontelez JAC, Jansen MPM, Barnighausen, Hauck K, Johansson KA, Meyer-Rath G, Over M, de Vlas SJ, van der Wilt GJ, Bijlmakers L and Baltussen RMPM. Evidence for scaling up HIV treatment in sub-Saharan Africa: A call for incorporating health system constraints. PLOS Medicine, February 2017, 1-5. Doi: 10.1371/journal.pmed.1002240
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5642329/

 

Murray TY, Sherman GG, Nakwa F, Macleod WB, Sipambo N, Velaphi S, Carmona S. Field Evaluation of Performance of Alere and Cepheid Qualitative HIV Assays for Pediatric Point-of-Care Testing in an Academic Hospital in Soweto, South Africa. Journal of Clinical Microbiology, November 2017, 55:11, pp3227-3235.doi.org/10.1128/JCM.01021-17
https://www.ncbi.nlm.nih.gov/pubmed/28855305

 

Nel JS, Lippincott CK, Berhanu R, Spencer DC, Sanne IM, Ive P. Does disseminated nontuberculosis mycobacterial disease cause false-positive Determine B-LAM lateral flow assay results? A retrospective review. Clinical Infectious Disease, June 2017, doi: 10.1093/cid/cix513. PMID: 28542080
https://www.ncbi.nlm.nih.gov/pubmed/28575238

 

Nicholls BR, Meyer Rath G. Cost-effectiveness of early identification of HIV infection. Open Access, thelancet.com, October 2017, Volume 4, e431-e432. 10.1016/s2352-3018(17)30129-7
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4536981/

 

Onoya D, Nattey C, Budgell E, van den Berg L, Maskew M, Evans D, Hirasen K, Long L, Fox MP. Predicting the Need for Third-Line Antiretroviral Therapy by Identifying Patients at High Tisk for Failing Second-Line Antiretroviral Therapy in South Africa. AIDS Patient Care and STDs, 2017 31:5, 205-212
https://www.ncbi.nlm.nih.gov/pubmed/28445088

 

Onoya D, Sineke T, Brennan AT, Long L, Fox MP. Timing of pregnancy, postpartum risk of Virologic failure and loss to follow-up among HIV-positive women. Open Access, AIDS. 201, 31:11, 1593-1602. 10.1097/QAD.0000000000001517
https://www.ncbi.nlm.nih.gov/pubmed/28463877

 

Padayatchi N, Naidu N, Friedland G, Naidoo K, Conradie F, Naidoo K, O’Donnell MR. Turning the tide against tuberculosis. International Journal of Infectious Diseases. 2017 Mar 31;56:6-9. 10.1016/J/IJID.2017.01.012
https://publichealth.yale.edu/people/gerald_friedland-2.profile

 

Pleaner M, Morroni C, Smit J, Lince-Deroche N, Chersich MF, Mullick S, Pillay D, Makua M and Rees H. Lessons learnt from the introduction of the contraceptive implant in South Africa. Open Access, SAMJ, November 2017 107:11.
http://www.samj.org.za/index.php/samj/article/view/12113

 

Rayne S,Lince-Deroche N,Hendrickson C,ShearerK, Mayo F, Michelow P,RubinG,Benn, C,Firnhaber C. Characterizingbreastconditionsatanopen-accessbreastclinicinSouth Africa:amodel thatismorethan cancercareforaresource-limitedsetting.BMCHealthServicesResearch, 17:63(2017). 10.1186/S12913-016-1959-4.
https://www.researchgate.net/publication/327708954_Breast_Cancer_Prevalence_Among_Patients_Referred_for_Ultrasound-Guided_Biopsy_at_Kenyatta_National_Hospital_Kenya

 

Rohner E, Sengayi M, Goeieman B, Michelow P, Firnhaber C, Maskew M, Bohlius J. Cervical cancer risk and impact of Pap-based screening in HIV-positive women on antiretroviral therapy in Johannesburg, South Africa. International Journal of Cancer. August 2017, 141:3, pp 488-496.
https://www.ncbi.nlm.nih.gov/pubmed/28440019

 

RosenS, FoxM,LarsonB,BrennanA,MaskewM,Tsikhutsu,BiiM,Ehrenkranz,P,Venter F. Simplifiedclinical algorithmforidentifyingpatientseligibleforimmediateinitiation ofantiretroviraltherapyforHIV(SLATE): protocolforarandomisedevaluation, BMJOpen7, 2017. 10.1136/bmjopen-2017-016340
https://bmjopen.bmj.com/content/7/5/e016340

 

Sawe, F., Hughes, M., Bao, Y., Hogg, E., Shaffer, D., Phulusa, J., Kakhu, T., Conradie, F., Kasaro, M., Mngqbisa, R., Siika, A., Atwiine, D., Chipato, T., McIntyre, J., Currier, J., & Lockman, S. (2017). Excellent retention, virologic and clinical outcomes after transitioning from an antiretroviral treatment clinical trial to locally-provided care and treatment in Africa. International Journal Of Clinical Trials, 4(1), 39-44. doi:http://dx.doi.org/10.18203/2349-3259.ijct20170307.
http://www.ijclinicaltrials.com/index.php/ijct/rt/captureCite/175/0/ApaCitationPlugin

 

Schnippel K, Firnhaber C, Berhanu R, Page-Shipp L, Sinanovic E. Adverse drug reactions during drug-resistant TB treatment in high HIV prevalence settings: a systematic review and meta-analysis.J Antimicrob Chemother. 2017 Apr 16. doi: 10.1093/jac/dkx107.
PMID:28419314
https://www.ncbi.nlm.nih.gov/pubmed/28419314

 

Schnippel K, Firnhaber C, Ndjeka N, Conradie F, Page-Shipp L, Berhanu R, Sinanovic E.
Persistently high early mortality despite rapid diagnostics for drug-resistant tuberculosis cases in South Africa.Int J Tuberc Lung Dis. 2017 Oct 1;21(10):1106-1111. doi: 10.5588/ijtld.17.0202.PMID:28911353
https://www.ncbi.nlm.nih.gov/pubmed/28911353

 

ShearerK,ClouseK,Meyer-RathG,MacleodW,MaskewM,Sanne I, LongL, Fox MP. Citizenshipstatusandengagement in HIV care:AnObservationalcohortstudytoassesstheassociationbetweenreportinganational 10numberand retentioninPublic-sectorHIVcareinJohannesburg,South Africa.BMJOpen2017;7:e013908(2017). 10.1136/bmjopen-2016-013908.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5278236/

 

ShearerK,EvansD,MayoF,RohrJK,Berhanu R,VanDenBerg L,Long L,SanneI,FoxMP. Treatmentoutcomes ofover1000 patientsonsecond-line,proteaseinhibitor-basedantiretroviraltherapyfrom fourpublic-sector HIV treatmentfacilities acrossJohannesburg,South Africa.Tropical Medicine andInternational Health, February 2017, Volume22no2 pp221-231. 10.1111/tmi.12804
https://www.ncbi.nlm.nih.gov/pubmed/27797443

 

Smith JS, Sanusi B, Swarts A, Faesen M, Levis S, Goeieman B, Ramotshela S, Rakhombe N, Williamson AL, Michelow P, Omar T, Hudgens MG, Firnhaber C. A randomised clinical trial comparing cervical dysplasia treatment with cryotherapy vs loop electrosurgical excision procedure in HIV: seropositive women from Johannesburg, South Africa. American Journal of Obstetrics and Gynecology. August 2017, 217:2, pp183, e1-183.e11. PMID: 28366730.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5886871/

 

Steegen K, Bronze M Papathanasopoulos MA, Van Zyl G, Goedhals D, Variava E, MacLeod W, Sanne I, Stevens WS, Carmona S. HIV-1 antiretroviral drug resistance patters in patients failing NNRTI-based treatment: results from a national survey in South Africa. Journal of Antimicrobiology Chemotherapy, January 2017, 72:1, pp 210-219.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5886871/

 

Stevens WS, Gous N, Macleod BW, Long LC, Variava E, Martinson N, Sanne I, Osih R and Scott L. Multi-disciplinary Point-of-Care Testing in South African Primary Health Care Clinics Accelerates HIV ART Initiation but Does Not Alter Retention in Care. JAIDS, September 2017, pp 65-73.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4157150/

 

Stoke A, Berry KM, Mchiza Z, Parker W, Labadarios D, Chola L, Hongoro C, Zuma K, Brennan AT, Rockers PC, Rosen S. Prevalence and unmet need for diabetes care across the care continuum in a national sample of South African adults: Evidence from the SANHANES-1, 2011-2012. PLoS One, October 2017.
https://www.ncbi.nlm.nih.gov/pubmed/28968435

 

TariqS,HoffmanS,RamjeeG,MantelJ,PhillipJ,BlanchardK,Lince-DerocheN,ExnerT.”Ididnotseeaneedtoget testedbefore,everythingwasgoingwellwithmyhealth”: aqualitativestudyofHIV-testingdecision-makingin Kwazulu-Natal,South Africa,AIDSCare(2017).
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5051894/

 

TenfordeMW,YadavA,DowdyDW,GupteN,ShivakotiR,Yang WT,MwelaseN,KanyamaC,PillayS,SamanekaW,SantosB, PoongulaliS,TripathyS, RiviereC,BerendesS,LamaJR, CardosoSW,SugandhavesaP,ChristianP,SembaRD,Campbell TB,GuptaA; NWCS319and ACTG5175studyteam.VitaminAandDDeficienciesAssociatedwithIncidentTuberculosisinHIV-InfectedPatientsInitiatingAntiretroviralTherapyinMultinationalCase-CohortStudy.JAcquirImmuneDefic Syndr. 2017Jul 1;75(3):e71-e79.doi:10.1097/QAI.0000000000001308.
PMID: 28169875;PubMedCentralPMCID:PMC5472489.
https://www.ncbi.nlm.nih.gov/pubmed/28169875